健康な被験者および軽度認知障害またはアルツハイマー病（AD）患者を対象としたLY2599666の研究

基本情報

NCT ID

NCT02614131

ステータス

中止

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

50

治験依頼者名

Eli Lilly and Company

概要

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's Disease (AD), and those with mild-to-moderate AD. The study will measure how much LY2599666 gets into the bloodstream and how long it takes the body to get rid of it. It will also evaluate how LY2599666 affects the body. The study has three parts. Part A will last about 2 months. Parts B and C will each last about 23 weeks. Participants may only enroll in one part.

対象疾患

介入

依頼者（Sponsor）